Pharmacological evidence for lithium-induced neuroprotection against methamphetamine-induced neurodegeneration via Akt-1/GSK3 and CREB-BDNF signaling pathways

Shafagh Mehrafza 1, Sareh Kermanshahi 1, Shahnaz Mostafidi 1, Majid Motaghinejad 2*, Manijeh Motevalian 3, Sulail Fatima 4

1 Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University (IUAPS), Tehran, Iran
2 Research Center for Addiction and Risky Behaviors (ReCARB), Iran Psychiatric Center, Iran University of Medical Sciences, Tehran, Iran
3 Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4 Department of Physiology, Tehran University of Medical Sciences-International Campus (TUMS-IC), Tehran, Iran

ARTICLE INFO

Article type: Original article

Article history:
Received: Apr 1, 2018
Accepted: Feb 17, 2019

Keywords:
Akt
BDNF
CREB
Lithium
Methamphetamine
GSK3

ABSTRACT

Objective(s): Neurodegeneration is an outcome of Methamphetamine (METH) abuse. Studies have emphasized on the neuroprotective properties of lithium. The current study is designed towards evaluating the role of Akt-1/GSK3 and CREB-BDNF signaling pathways in mediating lithium neuroprotection against METH-induced neurodegeneration in rats.

Materials and Methods: Sixty adult male rats were randomly divided into five groups: control group (received 0.7 ml normal saline per rat for 28 days), METH group (given 10 mg/kg of METH intraperitoneally for 28 days), groups 3, 4, and 5 (given METH (10 mg/kg) and lithium (75, 150, and 300 mg/kg intraperitoneally, individually for 28 days). Morris water maze (MWM) was used to assess mental functions. In addition to hippocampal neurodegeneration, Brain-derived neurotrophic factor (BDNF), cAMP response element binding (CREB) Glycogen synthase kinase 3 (GSK3), and Protein kinase B (Akt-1) were assessed in isolated hippocampus.

Results: METH abuse caused marked disorders in learning and memory that were dramatically improved with various doses of lithium. Furthermore, METH increased lipid peroxidation and the levels of oxidized form of interleukin 1 beta (IL-1β), glutathione (GSSG), Bax, tumor necrosis factor alpha (TNF-α), and GSK3, while attenuating the extent of glutathione (reduced form (GSH)), P-CREB, Bd-2, BDNF, and Akt-1 in the hippocampus. Moreover, METH declined superoxide dismutase (SOD), glutathione reductase (GR), and glutathione peroxidase (Gpx) activity in the hippocampus. Conversely, lithium attenuated METH-stimulated apoptosis, oxidative stress, and inflammation; while improving the extent of BDNF and P-CREB.

Conclusion: Probably lithium possesses neuroprotection against METH-stimulated neurodegeneration in the hippocampus via Akt-1/GSK3β and CREB/BDNF signaling pathways.

Please cite this article as:
Mehrafza Sh, Kermanshahi S, Mostafidi Sh, Motaghinejad M, Motevalian M, Fatima S. Pharmacological evidence for lithium-induced neuroprotection against methamphetamine-induced neurodegeneration via Akt-1/GSK3 and CREB-BDNF signaling pathways. Iran J Basic Med Sci 2019; 22:856-865.

doi: 10.22038/ijbms.2019.30855.7442

Introduction

Methamphetamine (METH), a neurostimulator agent, is widely misused all over the world. The concerns of prolonged use of METH and its biochemical and behavioral effects are still imprecise (1-4). The release of norepinephrine, dopamine, and to a lesser degree serotonin into synaptic terminals is increased via METH. Furthermore, the consequences of METH abuse are hyper-activation of dopaminergic receptors in the acute phases and down-regulation of these receptors in the chronic phase (4,5). The high risk of addiction and misuse of METH is caused by similarity of its biological action, compared to cocaine (5). According to investigations on experimental rodent models, chronic abuse of METH and its derivatives can prompt behavioral changes such as mood disorder and cognitive (learning and memory) damage (6-8). Also, studies have established the potential effect of METH in neurodegeneration of some brain areas such as the hippocampus, which is intensely connected with cognitive processes (7). Moreover, previous studies have displayed that METH abuse can stimulate apoptotic pathways and consequently, cause DNA fragmentation in brain cells (9, 10). It is well-known that METH and other neuro stimulants can prompt inflammation, mitochondrial malfunction, and oxidative stress in brain cells, though, the supposed mechanism are still unknown (11, 12). The Food and Drug Administration (FDA) has approved lithium as the first drug for maintenance therapy of bipolar disorder. Its actions of mood stabilization and manic and depressive prevention are regulated by calcium homeostasis, electrical excitation, neurotransmission, arachidonic acid metabolism, protein kinase C, and adenylyl cyclase system signaling (13). Furthermore, lithium impedes glycogen synthase kinase 3β (GSK-3), an enzyme associated with the inhibition of several cell survival factors such as cyclic AMP response element binding protein (CREB) and β-catenin (14-18). CREB regulates

*Corresponding author: Majid Motaghinejad, Research Center for Addiction and Risky Behaviors (ReCARB), Iran Psychiatric Center, Iran University of Medical Sciences, Tehran, Iran. Tel/Fax: +98-21-88622696; Email: m-motaghinejad@razi.tums.ac.ir
genes related with survival of neurons, neuroprotection, and neural plasticity such as brain-derived neurotrophic factor (BDNF) (19). Other than its anti-apoptotic action, lithium carries profound antioxidant, anti-inflammatory (14, 20), and neuroprotective potential (14, 20, 21). It has also been shown to reduce the drug abuse-stimulated increase in IL-1β, TNF-α, and apoptotic factor levels (20), through chronic treatment. Lithium-induced cognitive enhancements are also emphasized by human and animal-based studies (22). It is proposed that lithium may protect hippocampal neurons against METH-stimulated oxidative stress, apoptosis, and inflammation impairment through up-regulation of BDNF and CREB and regulation of Akt-1 and GSK3, but this mechanism has not been ascertained definitely. Given the importance of Akt-1/GSK3 and P-CREB/BDNF signaling pathways in conferring cognitive functions and neuroprotection, we designed this study to evaluate the role of these paths intermediating lithium-induced neuroprotection in contrast to methamphetamine stimulated inflammation, oxidative stress, apoptosis, and cognitive disturbances. This study is of specific status as it offers a vision into the disorders related to METH abuse and neuroprotective action of lithium against such disturbances.

Materials and Methods

Animals
Sixty adult Wistar male rats, weighing 250–300 g, were attained from the Experimental Research Center (Iran University of Medical Sciences). All animals were housed under controlled conditions with 22 ± 0.5 °C; 12-hr light/dark rotation and had access to food and water ad libitum. The experimental procedure was approved by the Research Council of Iran University of Medical Sciences, Tehran, Iran (This research is supplementary data from PhD thesis with code number: 14 and Research Code:6237). The experiment was planned as stated in ARRIVE (Animal Research: Reporting of In vivo Experiments) guiding principle, and all technical and ethical aspects were taken into account (23, 24).

Drug

Lithium and methamphetamine were obtained from the Sigma-Aldrich company and used as soon as prepared.

Experimental design

- **Group 1** (control) received normal saline (0.7 ml/rat, IP) for 28 days.
- **Group 2** (methamphetamine) received methamphetamine (10 mg/kg, IP) for 28 days.
- **Groups 3, 4, and 5** received methamphetamine (10 mg/kg, IP) and lithium (75, 150, and 300 mg/kg, IP separately) for 28 days, simultaneously.

The Morris Water Maze (MWM) test was done, during days 24 to 28, for evaluation of the effect of methamphetamine alone or in combination with lithium on memory and spatial learning. Once cognitive activity was evaluated (on day 28) and 24 hr after last administration of the drug, 50 mg/kg of sodium thiopental was intraperitoneally administrated for anaesthetization of rats. Afterward, total hippocampus was separated in order to detect bio-indicators of apoptosis, inflammation, and oxidative stress. The molecular and behavioral tests were done by the experimenter blinded to the animals’ identity.

Cognitive assessment

**Morris water maze (MWM) experiment**

The MWM apparatus, including a blackground tank (160 x 90 cm) filled with water was placed in the center of the experimental laboratory. This equipment was separated into four quadrants (North, East, West, and South) and water filled to 50 cm height. The blind experimenter waited in the North-East area of the room. A stand, with a length of 15 cm, was hidden and placed 1 cm below the water surface. During the training procedure (first four days), the mentioned stand was located randomly in one of the quadrants. A tracking system, automated with an infrared camera (CCTV B/W, SBC-300 (P), Samsung Electronics Co, Ltd, and Korea) was used to assess animal location in the tank. The camera was located 2.4 m above the water surface (25, 26).

A) Handling

Before the experiment and on the first day, for adaption of animals, all rats were located in the tank filled with 40 °C water (room temperature was 25±2°C), and the experimenter (blind) directed the rat to swim to the quadrant containing the stand. Throughout the experiment, the stand was placed in the tank, South-East quarter (25, 26).

B) Training procedure

In order to facilitate learning of stand’s position by animals, some external cues (for example a distinguishing window, picture, or door) were placed, as spatial cues, in the extra maze. The stand was placed in the South-East quarter of the MWM tank, which was located at a distance of 25 cm from the edge of the tank, and 1 cm beneath the water surface. Four trials per day during four consecutive days were performed on each rat for assessing the learning process. Each rat was randomly placed in one of the mentioned quadrants (North, East, West, and South). During learning time, if the stand was found by the rats within 60 sec, the trial was terminated automatically by the computer, but if they failed to find the stand within 60 sec, the trial was stopped by computer. For measuring learning time, three parameters were evaluated:

1. The time of escape latency, which is characterized by the time to find the hidden stand by the rat.
2. The distance traveled by each rat to reach the hidden stand.
3. Speed of each rat to reach the hidden stand.

C) Memory evaluation procedure

The procedure was done on the probe day (fifth day) where the stand was removed, and the animal was in the memory assessment phase. In this day animals were randomly frightened of the water from any of the directions mentioned above (almost East). Presence percentage of animals in the target quarter (South-East quarter in our experimental) was recorded and calculated (25-29).

Molecular assessment

**Mitochondrial preparations**

By administration of 50 mg/kg sodium thiopental, IP,
all animals were anesthetized, and the total hippocampus tissue was detached from each rat. After homogenization in cold buffer [25 mM 4-morpholinepropanesulfonic acid, 400 mM sucrose, 4 mM magnesium chloride (MgCl2), 0.05 mM ethylene glycol tetraacetic acid (EGTA), pH 7.3] the tissue was centrifuged at 450 × g for 10 min. Next, its supernatants were re-centrifuged at 12000 × g for 10 min. Lastly, the sediments were re-suspended in the stated homogenization buffer and kept at 0 °C. The amount of total mitochondrial proteins in tissues was determined, according to the guideline of DC protein assay commercial kit (Bio-Rad), (California, USA). For this valuation; Bradford reagent (1 part Bradford: 4 parts dH2O) was added serial dilutions (0.1-1.0 mg/ml) of a known protein sample concentration, e.g., bovine serum albumin (BSA) dissolved in homogenization buffer. These sequences of serial dilutions were used to generate a standard curve. Different quantities of 10, 15, 20, 25, and 30 μl of the protein extract (homogenized tissue solutions) were added to several wells. Bradford reagent was also added to each of them. Wells were read by the plate reader at 630 nm, to measure the density of colors. Using various BSA concentrations, the standard curve was drawn and used for measurement of the protein present in the extract. The homogenized solution, comprising mitochondria of the hippocampal cell tissue, was studied for evaluation of apoptosis, inflammatory biomarkers, and oxidative stress (17, 30).

**Measurement of oxidative stress biological markers**

**Evaluation of lipid peroxidation**

In order to evaluate lipid peroxidation, malondialdehyde (MDA), the main biomarker of lipid peroxidation was measured. Totally 100 μl of the lysis solution, SDS, was added to tubes that contained the sample solution (100 μl) or MDA standard. After shaking and incubation, 250 μl of thio barbituric acid (TBA) substance was added to each tube and incubated at 95 °C for 45–60 min. Afterward, the tubes were centrifuged at 1000 × g for 15 min, and 300 μl of n-butanol was added to 300 μl of the supernatant and then centrifuged for 5 min at 10,000 × g. Lastly, the absorbance of each tube was read at 532 nm, and the outcomes were expressed as nmol/mg of protein (18, 31-35).

**Measurement of GSH (Glutathione) and GSSG (Glutathione disulfide) disulfide**

To measure GSSG (glutathione disulfide) and GSH (glutathione) levels, 25 μl of the 1X glutathione reductase solution and 25 μl of the 1X NADPH solution were added to a 96-well plate comprising a standard solution of glutathione or mentioned homogenized sample solution. Next, 50 μl of the 1X chromogen was added to each well and mixed robustly. To end, the absorbance was read at 405 nm for each GSSG/GSH standard and sample. Quantities of GSSG/GSH were measured and reported as nmol/mg of protein, using the standard curve (18, 36).

**Measurement of manganese superoxide dismutase (MnSOD) function**

SOD activity was measured conferring to the previously described method (18, 36, 37), and was measured by the following standard equation: SOD activity = \{[(A blank 1 - A blank 3) – (A sample - A blank 2)]/ (A blank 1 - A blank 3)] × 100

**Measurement of glutathione peroxidase (GPx) function**

GPx activity was measured according to previous methods (18, 36, 37). It was measured according to absorbance change [ΔA340/min] and detected by the following equation: \( \Delta A_{340/min} = A_{340\ nm} \) (Start) – A340 nm (Stop)/ Reaction time (min), any alteration in the absorbance is directly related to GPx activity. GPx activity: \( \Delta A_{340/min} \times \) Dilution factor of the original sample / Extinction coefficient for NADPH at 340 nm× Volumes of the tested sample. Outcomes were described as mU /mg protein (18, 36, 37).

**Evaluation of glutathione reductase (GR) function**

GR function was measured as described previously (18, 36, 37) and its detection was based on the change in absorbance [ΔA340/min] by the subsequent equation: \( \Delta A_{340/min} = A_{340\ nm} \) (Start) – A340 nm (Stop)/ Reaction time (min), any variation in the absorbance is directly related to GR activity. GR activity: \( \Delta A_{340/min} \times \) Dilution factor of the original sample / Extinction coefficient for NADPH at 340 nm× Volumes of the tested sample. Outcomes were stated as mU/mg protein (18, 36, 37).

**Evaluation of protein expression/level alteration**

Concentrations (expression or level of protein) of cyclic adenosine monophosphate (cAMP) Response Element Binding Protein (CREB) (total and phosphorylated), brain-derived neurotrophic factor (BDNF), GSK3 (total and phosphorylated), Akt-1 (total and phosphorylated), TNF-α, IL-1β, Bcl-2, and Bax in cell lysate of hippocampal tissue, were measured by ELISA kits (Genzyme Diagnostics, Cambridge, USA). Concisely, first, wells containing sheep anti-rat BDNF,CREB (total and phosphorylated), IL-1β, and TNF-α polyclonal antibody (Sigma Chemical Co, Poole and Dorset, UK) were washed three times with washing buffer containing 0.5 M Sodium chloride (NaCl), 2.5 mM sodium dihydrogen phosphate (NaH2PO4), 7.5 mM NaHPO4, 0.1% Tween 20, pH 7.2. Then, 100 ml of 1% (w/v) ovalbumin (Sigma Chemical Co, Poole, Dorset, UK) solution was added to each well and incubated at 37 °C for 1 hr. After that following three washes, 100 ml of samples and standards were added to each well and incubated at 48 °C for 20 hr. Again After three washes, 100 ml of the biotinylated sheep anti- rat IL-1β or TNF-α antibody (1:1000 dilutions in washing buffer containing 1% sheep serum, Sigma Chemical Co, Poole, Dorset, UK) was added to each well. Next, after 1-hr incubation and three washes, 100 ml avidin-HRP (Dako Ltd, UK) (1:5000 dilution in wash buffer) was added to each well and the plate was incubated for 15 min. After washing three times, 100 ml of TMB substrate solution (Dako Ltd, UK) was added to each well and then incubated for 10 min at room temperature. Then, 100 ml of 1M H2SO4 was added, and absorbance was read at 450 nm. Results of TNF-α, IL-1β, Bax, and Bcl-2 in hippocampus tissues were reported as ng/ml, and CREB (total and phosphorylated), BDNF, Akt-1 (total and phosphorylated), and GSK3 (total and phosphorylated)
results were reported as pg/ml (38-41).

Statistical investigation

Data were evaluated using the GraphPad PRISM Software (version 6). Data were expressed as the mean ± standard error of the mean (SEM). Treatment and control group differences were first evaluated by ANOVA and followed by post hoc Tukey’s test. A P-value < 0.001 was considered statistically significant. The analysis was performed by a statistician blinded to the experimental groups.

Results

Results of changes in escape latency and distance traveled through training day in MWM

Compared to control groups (P < 0.001), METH (10 mg/kg) caused increased parameters of escape latency and traveled distance through the four days of training and learning in the MWM and this change was remarkable (Figures 1A and B). In contrast, lithium (150 and 300 mg/kg) repressed METH-stimulated significant reduction in escape latency and distance traveled (P < 0.001) (Figures 1A and B).

Results of changes in swimming speed through training days

During training trials, the swimming speed was comparable between the experimental groups (Figure 1C).

Results of percentage in the target quadrant in the probe trial

In comparison with the control group, METH (10 mg/kg), caused a noteworthy reduction in animals’ presence percentage, in the target quarter (P < 0.001) (Figure 1D). Also, lithium (150 and 300 mg/kg) can significantly diminish METH-induced reduction in animals’ presence in the target quarter (P < 0.001) (Figure 1D).

Effects of various doses of lithium on METH-induced GSH/GSSG variations

METH (10 mg/kg) treatment significantly decreased the mitochondrial GSH content while increasing the GSSG levels compared to the control group (P < 0.001) (Table 1). On the other hand, an increase in GSH-content and significantly reduced GSSG levels in METH-treated animals, in lithium at high doses (150 and 300 mg/kg) groups, was seen in comparison to the methamphetamine only treated group (P < 0.001) (Table 1).

Effects of various doses of lithium on METH-stimulated variation in oxidative stress parameters

There was a significant increase in MDA levels and decreased SOD, GPx, and GR activity after METH administration, compared to the control group (P < 0.001) (Table 2). On the other hand, high doses of lithium (150 and 300 mg/kg) attenuated METH-induced increase in MDA levels and reduced SOD, GPx, and GR activity (P < 0.001) (Table 2).

Effects of various doses of lithium on METH-stimulated rise in inflammatory biomarkers

METH, 10 mg/kg, caused a profound increase in levels of IL-1β and TNF-α when compared to the control group (P < 0.001) (Figures 2A and B). When compared to METH only treated group (P < 0.001) high doses of lithium (150 and 300 mg/kg) prevented these METH-induced rises in the levels of IL-1β and TNF-α.

Table 1. Effects of various doses of lithium on methamphetamine-induced GSH/GSSG alterations in hippocampal mitochondria

| Group          | GSH (nmol/mg of protein) | GSSG (nmol/mg of protein) | GSH/GSSG |
|----------------|--------------------------|---------------------------|----------|
| Control        | 65.2±5.1                 | 0.82±0.2                  | 79       |
| METH (10 mg/kg)| 38.5±3.1<sup>a</sup>     | 4.3±1.7<sup>b</sup>      | 8.8<sup>b</sup> |
| METH (10 mg/kg) + Li (75 mg/kg) | 44.5±3.5                | 3±0.9                    | 19       |
| METH (10 mg/kg) + Li (150 mg/kg) | 50.5±3<sup>a</sup>      | 1.93±0.13<sup>b</sup>   | 25<sup>b</sup> |
| METH (10 mg/kg) + Li (300 mg/kg) | 54.6±3.8<sup>b</sup>    | 1.63±0.19<sup>b</sup>   | 33<sup>b</sup> |

All data are given as mean ± SEM. a P < 0.001 vs control group, b P < 0.001 vs methamphetamine treated group.

METH: Methamphetamine; Li: Lithium; GSH: Reduced Glutathione; GSSG: Oxidized Glutathione.

Table 2. Effects of various doses of lithium on methamphetamine-induced oxidative stress in rats

| Groups          | MDA (nmol/mg of protein) | SOD (U/ml/mg of protein) | GPx (mU/mg of protein) | GR (mU/mg of protein) |
|-----------------|--------------------------|--------------------------|------------------------|-----------------------|
| Control         | 8.7±1.9                  | 81±7.9                   | 139±5                  | 133±7                |
| METH (10 mg/kg) | 18±2<sup>a</sup>         | 52±6<sup>b</sup>        | 119±7<sup>a</sup>      | 118±6<sup>a</sup>    |
| METH (10 mg/kg) + Li (75 mg/kg) | 15±1.8                  | 40±5                     | 125±8                  | 126±9                |
| METH (10 mg/kg) + Li (150 mg/kg) | 11±1.2<sup>a</sup>      | 71±5<sup>b</sup>        | 131±6<sup>b</sup>      | 132±8<sup>b</sup>    |
| METH (10 mg/kg) + Li (300 mg/kg) | 10±1.1<sup>b</sup>      | 75±6<sup>b</sup>        | 132±8<sup>b</sup>      | 133±7<sup>b</sup>    |

All data are given as mean ± SEM. a P < 0.001 vs control group, b P < 0.001 vs methamphetamine-treated group. MDA: Malonaldehyde; SOD: Superoxide dismutase; GR: Glutathione reductase; GPx: Glutathione peroxidase.
in IL-1β and TNF-α levels, which is a significant change (Figures 2 A and B).

Effects of various doses of lithium on METH-stimulated changes in Bax and Bcl-2 protein levels
There was increased Bax protein levels and attenuated Bcl-2 protein levels after METH (10 mg/kg) treatment when compared to the control group \( (P<0.001) \). In contrast, high doses of lithium (150 and 300 mg/kg) increased Bcl-2 while reducing Bax levels when compared to the METH only treated group \( (P<0.001) \) (Figures 3 A and B).

Discussion
Results show that lithium at various doses ameliorates METH-stimulated oxidative stress, neuro-apoptosis, and inflammation in the rat hippocampus. We also observed that the protecting effects of lithium were intermediated
at least in part through P-CREB /BDNF and Akt-1 /GSK3 signaling pathways. METH as a psycho-stimulant has a high potential for misuse and addiction (9, 42). The current study shows that prolonged administration of METH at a dose of 10 mg/kg can increase escape latency and distance traveled in MWM, suggestive of METH-induced learning deficits. Furthermore, in probe day, METH administration reduced the time percentage spent in the target quarter in MWM, suggestive of compromised spatial memory.

Our results approve the previous findings concerning METH-induced deficits in learning and memory in rats (9, 43). It has been shown that the release of dopamine, serotonin, and adrenaline in the brain has been stimulated by METH, which causes down-regulation of these amine receptors following cognitive impairment (43, 44). According to our results, lithium at high doses (40 and 80 mg/kg) reduced METH-stimulated cognition impairment. This protective influence of lithium on memory and learning has also been presented by previous studies (45, 46).
Our data indicated that administration of METH increased hippocampal MDA levels, whereas, lithium treatment (75, 150, and 200 mg/kg) attenuated METH-stimulated rise in lipid peroxidation in the brain. At higher doses (150 and 300 mg/kg) the suppressive influence of lithium on MDA levels was more profound compared to lower doses (75 mg/kg), used in this study. These outcomes are similar to previous findings, which have also shown METH-stimulated lipid peroxidation in the brain (9, 47). The adverse effects of METH are potentially mediated by its effect on mitochondria, and that lithium has the potential to reduce METH-induced toxicity, these results are confirmed by our studies and previous findings (48, 49). Moreover, it is well-evident that lithium has a role as a scavenger for free radicals in neurodegenerative diseases such as Alzheimer’s (49).

The results from this study indicated that METH (10 mg/kg) causes mitochondrial GSH decline while increasing GSSG levels in the hippocampal tissues. A key change that can promote neurodegenerative signals in the brain is activation of glutathione reduced form (GSH) to the toxic oxidized form (GSSG) by METH (50-53), and this mechanism adversely affects glutathione cycle and leads to neural cell death (51, 53). Furthermore, we found that various doses of lithium, particularly 150 and 300 mg/kg, increase GSH content while decreasing GSSG level in animals with METH (10 mg/kg) abuse. According to studies, neurprotective effects of lithium against neurodegenerative disorders is mediated via modulation of the glutathione cycle (54, 55).

In our study, administration of METH decreased GPx, GR, and SOD activities in isolated hippocampal tissues. Studies have also reported a reduction of antioxidant defenses with METH, which may result in neurodegeneration (43, 56). It has been shown that for transforming the oxidized form of glutathione (GSH) to the reduced form (GSSG), GR is the key enzyme (57). Consequently, METH-induced reduction in GR function results in an increase of GSSG and decrease of GSH levels as witnessed in this study. Several new reports presented that METH causes mitochondrial dysfunction that prompts antioxidant enzyme activity inhibition in multiple cells (9, 30, 43). We detected that lithium treatment helps in recovering the action of antioxidant enzymes in a dose-dependent manner. Lithium protects the brain against METH-stimulated oxidative stress by triggering GR, which increases the transformation of GSSG to GSH. The anti-oxidative properties of lithium in neurodegenerative disorders are well-known according to prior experimental studies (58, 59). Along with previous reports, our results confirmed METH-induced reduction in SOD activity (60). Conversely, lithium treatment elevated SOD activity thereby defending the tissue against oxidative impairment. Formerly, it was discovered that lithium was advantageous in reversing alcohol abuse-related decrease in SOD activity in the hippocampal tissues (54). We demonstrated that, in the hippocampal tissue, chronic METH administration profoundly induces the levels of pro-inflammatory cytokines like TNF-α and IL-β. However, lithium at high doses is likely to suppress METH-stimulated neuroinflammation. Our results approve previous reports regarding METH and other psychostimulants-induced increase in pro-inflammatory cytokines. It has been suggested that pro-inflammatory action of METH is accountable for its neurodegenerative properties (61). Conversely, lithium has been shown to target neuroinflammation signaling cascades, thus maintaining the brain against inflammation and related impairment (20).

Other than oxidative stress and inflammation, this study approves METH-induced apoptosis in the hippocampus. We witnessed that METH administration results in raised Bax apoptotic protein; however, it declines Bcl-2 anti-apoptotic protein. This data is in line with prior works that have demonstrated that METH misuse can cause brain impairment through activation of multiple apoptotic cascades (62, 63). In contrast, our study outcomes confirmed the anti-apoptotic influence of lithium against METH administration, as shown by reduced Bax and enhanced Bcl-2 expressions in the hippocampus. Earlier studies revealed that lithium treatment could reduce levels of cleaved caspase-3 and Bax and subsequent nuclear condensation that leads to neurodegeneration (16).

Previously, the anti-inflammatory, anti-apoptotic, and anti-oxidative properties of lithium have been described (20, 59); however, the involved signaling pathways persist unidentified. Concerning this, we assessed the role of the Akt-1/GSK3 and P-CREB-BDNF signaling pathways. According to our data METH administration decreases BDNF, CREB (total and phosphorylated), Akt-1 protein expression, and GSK3 level in the hippocampus. In contrast, lithium at high doses enhanced CREB (total and phosphorylated), BDNF and Akt-1 expression and GSK3 levels. Therefore, it can be predicted that treatment with lithium reestablishes the P-CREB-BDNF signaling cascade and keeps the brain against METH-simulated neurotoxicity. The P-CREB, as a transcription factor, adjusts over hundred genes, mainly BDNF which is strongly associated in neuronal regeneration, development, survival, excitability, addiction, depression, and cognition (30, 64). Additionally, it has been shown that dysregulation of CREB transcriptional cascade prompts oxidative stress, apoptosis, and neurodegeneration (64, 65). Several studies have stated that P-CREB (activated form of CREB) assists the expression of BDNF, a TrkB receptor ligand. Furthermore, stimulation of the TrkB receptor by BDNF prevents brain cell deterioration and progress endurance of neurons (66). This cascade signaling including P-CREB-BDNF has also been linked to cognitive functions, mood balances, and reward mechanisms (66-69). In the present study, METH reduced activity of BDNF/TrkB signaling pathway and stimulates neurodegeneration, apoptosis, inflammation, and oxidative stress. In contrast, there seems to be an improvement in P-CREB/BDNF/TrkB signaling with lithium administration, thus protecting the hippocampus against METH-induced toxic harm. Glycogen synthase kinase-3 (GSK-3) dysfunction is associated with numerous brain diseases, mainly with neuronal apoptosis, neurodegeneration, and cognitive damage. Stimulation of phosphatidylinositol 3-kinase (PI3K) and following phosphorylation of Akt-1 (Protein Kinase B) inhibits GSK-3. Additionally, inhibition of GSK-3 is related to neuronal survival and mood stabilization. In the current study, we witnessed an increase in GSK3 and reduction in AKT-1 expression by METH abuse. On
the contrary, lithium-treated animals revealed improved AKT-1 expression and lower expression of GSK3.

**Conclusion**

Taken together, for the first time, the outcomes of the present study display that lithium treatment, probably through stimulation of P-CREB-BDNF and Akt-1/GSK3 signaling pathways, can attenuate METH-induced apoptosis, inflammation, and oxidative stress. Though, additional studies concerning toxicity and human dosage are required.

**Conflicts of Interest**

None to declare.

**Acknowledgment**

This research was financially supported by Razi Drug Research center, Iran University of Medical Sciences, Tehran, Iran.

**References**

1. Darke S, Darke S, Kaye S, Darke S, Kaye S, McKetin R, et al. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008; 27:253-262.

2. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006; 31:301-313

3. Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C, et al. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PloS One 2010;5:e8790.

4. Volkow ND, Chang L, Wang G-J, Fowler JS, Leonardo-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-382.

5. Th rash B, Karuppagounder SS, Uthayahs S, Suppiramaniam V, Dhanasekaran M. Neurototoxic effects of methamphetamine. Neuroch Ros. 2010;35:171-179.

6. Brecht M-L, O’Brien A, Von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addictive Behaviors 2004;29:89-106.

7. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 2003;119:767-775.

8. Nouri M, Movassagh S. Protective effect of pentoxifylline on male wistar rat testicular germ cell apoptosis induced by 3,4-methylenedioxymethamphetamine. Iran J Basic Med Sci 2016;19:646-652.

9. Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotox Res 2005;8:199-206.

10. Wu CW, Ping YH, Yen JC, Chang CY, Wang SF, Yeh CL, et al. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicol Appl Pharmacol 2007;220:243-251.

11. Zhang X, Banerjee A, Banks WA, Erkal N. N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res. 2009;1275:87-95.

12. Jummongprakhon P, Govitrapong P, Tocharus C, Tocharus J. Melatonin promotes blood-brain barrier integrity in methamphetamine-induced inflammation in primary rat brain microvascular endothelial cells. Brain Res. 2016;1646:182-192.
29. Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in Alzheimer’s disease model mice. J Vis Exp: JoVE 2011. doi: 10.3791/2920.

30. Motaghinejad M, Motevalian M, Abdollahi M, Heidari M, Madjz Z. Topiramate confers neuroprotection against methylphenidate-induced neurodegeneration in dentate gyrus and CA1 regions of Hippocampus through CREB/BDNF pathway in rats. Neurotox Res 2013;13:373-399.

31. Motaghinejad M, Motevalian M, Fatima S, Hashemi H, Gholami M. Curcumin confers neuroprotection against alcohol-induced hippocampal neurodegeneration through CREB-BDNF pathway in rats. Biomed Pharmacother. 2017;87:721-740.

32. Motaghinejad M, Seyyedjavadein Z, Motevalian M, Asadi M. The neuroprotective effect of lithium against high dose methylphenidate: possible role of BDNF. Neurotoxicology 2016;56:40-54.

33. Motaghinejad M, Motevalian M, Fatima S, Faraji F, Mozaffari S. The neuroprotective effect of curcumin against nicotine-induced neurotoxicity is mediated by CREB–BDNF signaling pathway. Neurochem Res 2017;42:2921-2932.

34. Motaghinejad M, Karimin SM, Motaghinejad O, Shabab B, Asadighaleni M, Fatima S. The effect of various morphine weaning regimens on the sequelae of opioid tolerance involving physical dependency, anxiety and hippocampus cell neurodegeneration in rats. Fundam Clin Pharmacol 2015;29:299-309.

35. Motaghinejad M, Motevalian M, Fatima S. Mediator role of NMDA, AMPA/kainate, GABAA and Alpha2 receptors in topiramate neuroprotective effects against methylphenidate induced neurotoxicity in rat. Life Sci 2017;179:37-53.

36. Motaghinejad M, Motevalian M, Falak R, Heidari M, Sharzad M, Kalantari E. Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway. J Neuro Transm (Vienna) 2016;123:1463-1477.

37. Motaghinejad M, Motevalian M, Babalouei F, Abdollahi M, Heidari M, Madjz Z. Possible involvement of CREB/BDNF signaling pathway in neuroprotective effects of topiramate against methylphenidate induced apoptosis, oxidative stress and inflammation in isolated hippocampus of rats: molecular, biochemical and histological evidences. Brain Res Bull 2017;132:82-98.

38. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273-279.

39. Demircan N, Safran B, Soylu M, Ozcan A, Sizmaz S. Determination of vireous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006;20:1366-1369.

40. Shi YQ, Huang TW, Chen LM, Zhang J, Zhu YG, et al. Ginsenoside Rg1 attenuates amyloid-β content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 2010;19:977-989.

41. Lee B-H, Kim H, Park S-H, Kim Y-K. Decreased plasma BDNF level in depressive patients. J Affect Disord 2007;101:239-244.

42. Bruin JE, Gerstein HC, Holloway AC. Long-term consequences of fetal and neonatal nicotine exposure: a critical review. Toxicol Sci 2010;116:364-374.

43. Gonçalves J, Baptista S, Martins T, Milhazes N, Borges F, Ribeiro CF, et al. Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci 2010;31:315-326.

44. Johnson BA, Roache JD, Alt-Daoud N, Wallace C, Wells LG, Wang Y. Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. Psychopharmacology (Berl) 2005;178:296-302.

45. Kutzer SP. Lithium and Cognition. J Child Adolesc Psychopharmacol 2004;9:8-15.

46. Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology (Berl) 2003;170:225-234.

47. Brown JM, Quinton MS, Yamamoto BK. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J Neurochem 2005;95:429-436.

48. Mashayekhi V, Eskandari MR, Kobarfard F, Khajeamir A, Hosseini M-J. Induction of mitochondrial permeability transition (MPT) pore opening and ROS formation as a mechanism for methamphetamine-induced mitochondrial toxicity. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:47-58.

49. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alessi S, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neursychopharmacol. 2009;12:805-22.

50. Zitka O, Skalickova S, Gumulec J, Masarik M, Adam V, Hubalek J, et al. Redox status expressed as GSH: GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol Lett.2012;4:1247-53.

51. Griffith OW, Meister A, Origin and turnover of mitochondrial glutathione. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:4668.

52. Harold C, Wallace T, Friedman R, Gudelsky G, Yamamoto B. Methamphetamine selectively alters brain glutathione. Eur J Pharmacol 2000;400:99-102.

53. Moszczynska A, Turetne S, Kish SJ. Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine. Neurosci Lett 1998;255:49-52.

54. Maurer IC, Schippel P, Volz HP. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 2009;11:515-22.

55. Cui J, Shao L, Young LT, Wang JF. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007;144:1447-1453.

56. Imam SZ, Ali SF. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation. Brain Res 2000;855:186-191.

57. Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol 2009;117:63-73.

58. Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011;4:15.

59. Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat 2013;9:493-500.

60. Huang MC, Lin SK, Chen CH, Pan CH, Lee CH, Liu HC. Oxidative stress status assessed during lithium treatment in patients with bipolar disorder. J Affect Disord 2016;186:143-148.
striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 2002;42:837-845.
64. Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005;28:436-445.
65. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609.
66. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003;302:890-893.
67. Yoshii A, Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 2010;70:304-322.
68. Cao G, Zhu J, Zhong Q, Shi C, Dang Y, Han W, et al. Distinct roles of methamphetamine in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of ERK and CREB activation in hippocampus and prefrontal cortex. Neuropharmacol. 2013;67:144-154.
69. Razavi BM, Sadeghi M, Abnous K, Vahdati F, Hosseinzadeh H. Study of the role of CREB, BDNF, and VGF neuropeptide in long term antidepressant activity of crocin in the rat cerebellum. Iran J Pharm Res 2017;16:1452-1462.